Protective Effect of Asacol in Combination with Pantoprazole in Ulcerative Colitis Patients Who Defecate Asacol Tablets Intactly: A Clinical Trial Study

References

• Chaparro M, Gisbert JP. Maintenance therapy options for ulcerative colitis. Expert Opin Pharmacother. 2016;17(10):1339–1349. doi:10.1080/14656566.2016.1187132
   PubMed Web of Science ®Google Scholar
• Newton A, Kumar N. IBD–impact of colonic pH, onset of action and other factors in modern therapeutic approach. Interdiscip J Microinflammation. 2014;1:116. doi:10.4172/ijm.1000116
   Google Scholar
• Awaad AS, El-Meligy RM, Soliman GA. Natural products in treatment of ulcerative colitis and peptic ulcer. J Saudi Chem Soc. 2013;17(1):101–124. doi:10.1016/j.jscs.2012.03.002
   Web of Science ®Google Scholar
• Sairenji T, Collins KL, Evans DV. An update on inflammatory bowel disease. Prim Care. 2017;44(4):673–692. doi:10.1016/j.pop.2017.07.010
   PubMed Web of Science ®Google Scholar
• Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000;95(5):1263–1276. doi:10.1111/j.1572-0241.2000.01940.x
   PubMed Web of Science ®Google Scholar
• Ye B, van Langenberg DR. Mesalazine preparations for the treatment of ulcerative colitis: are all created equal? World World J Gastrointest Pharmacol Ther. 2015;6(4):137–144. doi:10.4292/wjgpt.v6.i4.137
   PubMedGoogle Scholar
• Ham M, Moss AC. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol. 2012z;5(2):113–123. doi:10.1586/ecp.12.2
   PubMed Web of Science ®Google Scholar
• Nugent S, Kumar D, Rampton D, Evans D. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut. 2001;48(4):571–577. doi:10.1136/gut.48.4.571
   PubMed Web of Science ®Google Scholar
• Testa A, Castiglione F, Nardone OM, Colombo GL. Adherence in ulcerative colitis: an overview. Patient Prefer Adherence. 2017;11:297–303. doi:10.2147/PPA
   PubMed Web of Science ®Google Scholar
• Zheng G. A study on the curative effect of omeprazole in the treatment of ulcerative colitis. Int J Clin Exp Med. 2017;1(3):17.
   Google Scholar
• Bardou M, Martin J. Pantoprazole: from drug metabolism to clinical relevance. Expert Opin Drug Metab Toxicol. 2008;4(4):471–483. doi:10.1517/17425255.4.4.471
   PubMed Web of Science ®Google Scholar
• Dong Y, Zhou Z, Ding H, Zhang S. Preparation and properties of a pH sensitive carrier based on three kinds of polymer blend to control the release of 5-amino salicylic acid. Pharm Dev Technol. 2014;19(8):960–967. doi:10.3109/10837450.2013.846372
   PubMed Web of Science ®Google Scholar
• Malekzadeh MM, Vahedi H, Gohari K, et al. Emerging epidemic of inflammatory bowel disease in a middle income country: a nation-wide study from Iran. Arch Iran Med. 2016;19(1):2–15.
   Web of Science ®Google Scholar
• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769–2778. doi:10.1016/S0140-6736(17)32448-0
   PubMed Web of Science ®Google Scholar
• Zobeiri M, Bashiri H, Askari L, et al. Epidemiologic characteristics of patients with inflammatory bowel disease in Kermanshah, Iran. Middle East J Dig Dis. 2017;9(3):164–169. doi:10.15171/mejdd.2017.68
   Google Scholar
• Kedika RR, Souza RF, Spechler SJ. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci. 2009;54(11):2312–2317. doi:10.1007/s10620-009-0951-9
   PubMed Web of Science ®Google Scholar
• Kim YJ 1, Lee JS, Hong KS, Chung JW, Kim JH, Hahm KB. Novel application of proton pump inhibitor for the prevention of colitis-induced colorectal carcinogenesis beyond acid suppression. Cancer Prev Res (Phila). 2010;3(8):963–974. doi:10.1158/1940-6207.CAPR-10-0033
   PubMed Web of Science ®Google Scholar
• Hauso Q, Christian Martinsen T, Waldum H. 5-Aminosalicylic acid, a specific drug for ulcerative colitis. Scand J Gastroenterol. 2015;50(8):933–941. doi:10.3109/00365521.2015.1018937
   PubMed Web of Science ®Google Scholar
• Verma S, Kumar V, Mishra DN, Singh SK. Colon targeted drug delivery: current and novel perspectives. Int J Pharm Sci Res. 2012;3(5):1274–1284.
   Google Scholar
• Hua S, Marks E, Schneider JJ, Keely S. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Nanomedicine. 2015;11(5):1117–1132. doi:10.1016/j.nano.2015.02.018
   PubMed Web of Science ®Google Scholar
• Raimundo AH, Evans DF, Rogers J, Silk DBA. Gastrointestinal pH profiles in ulcerative colitis. Gastroenterology. 1992;102:A681.
   Google Scholar
• Fallingborg J, Christensen LA, Ingeman-Nielsen M, Jacobsen BA, Abildgaard K, Rasmussen HH. pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther. 1989;3(6):605–613. doi:10.1111/j.1365-2036.1989.tb00254.x
   Google Scholar
• Abinusawa A 1, Tenjarla S. Release of 5-aminosalicylic acid (5-ASA) from mesalamine formulations at various pH levels. Adv Ther. 2015;32(5):477–484. doi:10.1007/s12325-015-0206-4
   Web of Science ®Google Scholar
• Wiltink EH, Mulder CJ, Stolk LM, Rietbroek R, Verbeek C, Tytgat GN. Absorption of oral mesalazine-containing preparations and the influence of famotidine on the absorption. Scand J Gastroenterol. 1990;25(6):579–584. doi:10.3109/00365529009095533
   PubMed Web of Science ®Google Scholar
• Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash). 2000;40(1):52–62; 121–3. doi:10.1016/S1086-5802(16)31036-1
   Google Scholar
• Ferreiro JL, Ueno M, Tomasello SD, et al. Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. Circ Cardiovasc Interv. 2011;4(3):273–279. doi:10.1161/CIRCINTERVENTIONS.110.960997
   PubMed Web of Science ®Google Scholar
• Suzuki H, Miyazawa M, Nagahashi S, et al. Rabeprazole treatment attenuated Helicobacter pylori‐associated gastric mucosal lesion formation in Mongolian gerbils. J Gastroenterol Hepatol. 2003;18(7):787–795. doi:10.1046/j.1440-1746.2003.03038.x
   Web of Science ®Google Scholar
• Yang Y, Chua KL. Assessment of the effect of efflux pump inhibitors on in vitro antimicrobial susceptibility of multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2013;42(3):283–284. doi:10.1016/j.ijantimicag.2013.05.011
   Web of Science ®Google Scholar